Page last updated: 2024-10-26

donepezil and Bone Loss, Osteoclastic

donepezil has been researched along with Bone Loss, Osteoclastic in 1 studies

Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Li, S1
Teguh, D1
Wu, D1
Liu, L1
Hu, C1
Yuan, J1
Inderjeeth, CA1
Xu, J1

Other Studies

1 other study available for donepezil and Bone Loss, Osteoclastic

ArticleYear
Antidementia medication acetylcholinesterase inhibitors have therapeutic benefits on osteoporotic bone by attenuating osteoclastogenesis and bone resorption.
    Journal of cellular physiology, 2023, Volume: 238, Issue:8

    Topics: Acetylcholinesterase; Animals; Bone Resorption; Cell Differentiation; Cholinesterase Inhibitors; Don

2023